Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.

[1]  M. Morrow,et al.  Results of hospital cancer registry surveys by the American College of Surgeons , 1997, Cancer.

[2]  L. Shamel,et al.  Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. , 1996, Urology.

[3]  J. Oesterling,et al.  The effect of finasteride on prostate specific antigen: review of available data. , 1996, The Journal of urology.

[4]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[5]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[6]  H. Guess,et al.  Treatment of Benign Prostatic Hyperplasia with 5α-Reductase Inhibitors , 1995 .

[7]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[8]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[9]  J. Isaacs.  5Alpha-reductase inhibitors and the treatment of benign prostatic hyperplasia , 1993 .

[10]  H. Guess,et al.  The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasia , 1993, The Prostate.